News
ZLDPF
50.00
NaN%
--
Zealand Pharma price target lowered to DKK 435 from DKK 460 at JPMorgan
TipRanks · 4d ago
Weekly Report: what happened at ZLDPF last week (0817-0821)?
Weekly Report · 5d ago
Weekly Report: what happened at ZLDPF last week (0810-0814)?
Weekly Report · 08/17 09:24
Zealand Pharma price target raised to DKK 420 from DKK 410 at Wells Fargo
TipRanks · 08/16 14:15
Zealand Pharma GAAP EPS of DKK55.34, revenue of DKK4.49B
Seeking Alpha · 08/13 19:55
Zealand gains $100M in funding from Royalty Pharma
Seeking Alpha · 08/12 21:16
Weekly Report: what happened at ZLDPF last week (0803-0807)?
Weekly Report · 08/10 09:22
Zealand Pharma’s Dasiglucagon Study Moves Forward in Rare Childhood Disease
TipRanks · 08/03 16:30
Weekly Report: what happened at ZLDPF last week (0727-0731)?
Weekly Report · 08/03 09:22
Zealand Pharma’s New Psoriasis Trial Sets Early Stage for ZP9830
TipRanks · 07/29 16:32
Weekly Report: what happened at ZLDPF last week (0720-0724)?
Weekly Report · 07/27 09:24
Zealand Pharma Advances First-in-Human Obesity Drug Trial With ZP6590
TipRanks · 07/24 16:34
Weekly Report: what happened at ZLDPF last week (0713-0717)?
Weekly Report · 07/20 09:23
Zealand Pharma downgraded to Hold from Buy at Jefferies
TipRanks · 07/13 23:25
Weekly Report: what happened at ZLDPF last week (0706-0710)?
Weekly Report · 07/13 09:23
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
Seeking Alpha · 07/09 12:46
Weekly Report: what happened at ZLDPF last week (0629-0703)?
Weekly Report · 07/06 09:24
Weekly Report: what happened at ZLDPF last week (0622-0626)?
Weekly Report · 06/29 09:23
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
Benzinga · 06/22 11:15
Weekly Report: what happened at ZLDPF last week (0615-0619)?
Weekly Report · 06/22 09:26
More
Webull provides a variety of real-time ZLDPF stock news. You can receive the latest news about Zealand Pharma A/S through multiple platforms. This information may help you make smarter investment decisions.
About ZLDPF
Zealand Pharma A/S is a Denmark-based biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines. The Company's activities are organized around three therapeutic areas: Obesity and Related Comorbidities, which includes obesity and metabolic disease therapies; Rare Diseases, which develops treatments for congenital hyperinsulinism and short bowel syndrome; and Inflammation, which focuses on therapies for chronic inflammatory and autoimmune diseases. Zealand Pharma conducts research and development activities internally and through strategic collaborations with pharmaceutical partners, including Roche and Boehringer Ingelheim.